Press

Seven organisations present a technical report supporting the need to review the implementation of the Urban Wastewater Treatment Directive

21/09/2026

Healthcare · Industrial biotechnology · Bioeconomy · Circular economy

• The report is presented at a time of growing European debate over the implementation of the Directive, following the European Parliament’s call for a new assessment and the recent conclusions of the Advocate General of the Court of Justice of the European Union, which question aspects of the allocation of responsibilities to the pharmaceutical and cosmetics sectors.
• The associations share the environmental objectives of the Directive but call for a prudent and legally robust transposition based on proportionality and sound scientific evidence.

AseBio

Biomarkers and artificial intelligence open new avenues for anticipating Alzheimer’s progression

21/09/2026

Healthcare · In vitro diagnostics · Personalized medicine

• In Spain, nearly one million people were living with dementia in 2025, according to estimates from Alzheimer Europe, with Alzheimer’s disease accounting for between 60% and 70% of cases.
• Biotechnology, new biomarkers and artificial intelligence are making it possible to integrate increasing amounts of information to characterise patients and move towards earlier and more personalised approaches.
• To mark World Alzheimer’s Day, AseBio explores these advances together with its member ADmit Therapeutics, which has developed MAP-AD®, a test designed to predict progression from mild cognitive impairment to Alzheimer’s disease dementia.

AseBio

Sepsis causes 11 million deaths every year, while new biomarkers are paving the way for a more precise approach

13/09/2026

Healthcare · In vitro diagnostics · Personalized medicine

• In Spain, around 50,000 people are affected by sepsis each year and approximately 17,000 die, highlighting the significant impact of this medical emergency.
• Biotechnology is driving the development of new biomarkers and diagnostic tools to detect the risk of deterioration earlier, understand each patient’s immune response and advance towards precision medicine.
• On World Sepsis Day, AseBio brings together the perspectives of clinical experts, researchers and our partner Viva In Vitro Diagnostics to analyse the main current challenges and the future of sepsis management.

AseBio

Biotechnology opens up new pathways to regenerate soils and increase crop resilience

09/09/2026

Climate change · Agrifood · Food & feed · Agriculture

• Agriculture is facing increasing pressure on soil and water resources, with more than 60% of human-induced land degradation occurring on agricultural land.
• Biotechnology innovation has a key role to play in advancing towards more sustainable and regenerative agriculture, capable of restoring soil health and fertility, improving resource management and increasing crop resilience.
• On the occasion of World Agriculture Day, we spoke with our member Phoenix Biosolutions, which develops biotechnology solutions based on microalgae and biostimulants, to explore how these innovations can contribute to more sustainable, regenerative and resilient agriculture.

AseBio

BIOSPAIN 2026 to turn Bilbao into Europe's hub for debating the future of biotechnology

21/07/2026

Healthcare · Bioeconomy · International · BioSpain

• The conference programme will address the sector's major challenges, from advanced therapies and artificial intelligence to the bioeconomy and innovation financing.
• From 29 September to 1 October, the event will bring together companies, researchers, investors and institutions from more than 30 countries.
• Exhibition space remains available, offering a key platform for fostering strategic partnerships and new business opportunities.

AseBio

AseBio welcomes progress in the european reform of genetically modified microorganism legislation and calls for maintaining regulatory ambition

13/07/2026

Healthcare · Agrifood · Food & feed · Agriculture

• The European regulatory framework for genetically modified microorganisms (GMMs) is undergoing an update to keep pace with scientific and technological advances.
• In this context, the European Commission presented a legislative package in 2025 to modernise this regulatory framework. The process has now moved forward with the Council of the European Union adopting its negotiating position on the proposed Directive amending the legislation governing the deliberate release into the environment and the placing on the market of GMMs.
• AseBio believes the reform is moving in the right direction, while calling for regulatory ambition to be maintained throughout the negotiations in order to strengthen European innovation and competitiveness.

AseBio

Zoonotic diseases highlight the need to strengthen prevention and the One Health approach to future health threats

06/07/2026

Healthcare · Climate change · Animal health · Industrial biotechnology

• Around 60% of human infectious diseases originate in animals. Climate change and globalization are reinforcing the need to improve prevention.
• In this context, biotechnology must be recognized as a strategic sector, as greater preparedness and stronger collaboration enhance our ability to anticipate and respond to future public health emergencies.
• On World Zoonoses Day, we spoke with HIPRA, one of the European biotechnology companies most strongly committed to the One Health approach.

AseBio

Research on the TDP-43 protein opens new therapeutic avenues for ALS

20/06/2026

Healthcare · Rare diseases · Innovative drugs · Personalized medicine

• Biotechnology is driving new strategies to combat ALS, including research on the TDP-43 protein, a key target involved in the majority of cases of the disease.
• Molefy Pharma, an AseBio member company, is developing AP-2, an experimental therapy for ALS aimed at restoring the function of the TDP-43 protein. The company has already received orphan drug designation from the EMA and authorization from the Spanish Agency for Medicines and Medical Devices (AEMPS) to begin clinical trials in humans.
• “Today, ALS can be defined as a TDP-43 proteinopathy, that is, a disease of the TDP-43 protein,” says Alfonso de Egaña Barrenechea, CEO of Molefy Pharma.

AseBio

AseBio is involved in three key European initiatives aimed at boosting biotechnology competitiveness and scaling

16/06/2026

Industrial biotechnology · International · Financing

• We have contributed to the Fraunhofer Institute’s technical questionnaire on the Biotech Act II, the European Commission’s public consultation on this forthcoming legislative initiative, and the feedback process for the Food & Feed Safety Simplification Omnibus.
• The success of the Biotech Act II will depend on its ability to transform Europe’s scientific excellence into investment, industrial capacity, and market-ready products through adequate funding and a simpler, more harmonized regulatory environment.
• Through our contributions to the Food & Feed Safety Simplification Omnibus, we advocate for regulatory simplification that provides legal certainty, reduces fragmentation among Member States, and facilitates the market entry of new biotechnological solutions.

AseBio